602 related articles for article (PubMed ID: 12089448)
1. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning.
Aiuti A; Slavin S; Aker M; Ficara F; Deola S; Mortellaro A; Morecki S; Andolfi G; Tabucchi A; Carlucci F; Marinello E; Cattaneo F; Vai S; Servida P; Miniero R; Roncarolo MG; Bordignon C
Science; 2002 Jun; 296(5577):2410-3. PubMed ID: 12089448
[TBL] [Abstract][Full Text] [Related]
2. Gene therapy for immunodeficiency due to adenosine deaminase deficiency.
Aiuti A; Cattaneo F; Galimberti S; Benninghoff U; Cassani B; Callegaro L; Scaramuzza S; Andolfi G; Mirolo M; Brigida I; Tabucchi A; Carlucci F; Eibl M; Aker M; Slavin S; Al-Mousa H; Al Ghonaium A; Ferster A; Duppenthaler A; Notarangelo L; Wintergerst U; Buckley RH; Bregni M; Marktel S; Valsecchi MG; Rossi P; Ciceri F; Miniero R; Bordignon C; Roncarolo MG
N Engl J Med; 2009 Jan; 360(5):447-58. PubMed ID: 19179314
[TBL] [Abstract][Full Text] [Related]
3. Outcomes in two Japanese adenosine deaminase-deficiency patients treated by stem cell gene therapy with no cytoreductive conditioning.
Otsu M; Yamada M; Nakajima S; Kida M; Maeyama Y; Hatano N; Toita N; Takezaki S; Okura Y; Kobayashi R; Matsumoto Y; Tatsuzawa O; Tsuchida F; Kato S; Kitagawa M; Mineno J; Hershfield MS; Bali P; Candotti F; Onodera M; Kawamura N; Sakiyama Y; Ariga T
J Clin Immunol; 2015 May; 35(4):384-98. PubMed ID: 25875699
[TBL] [Abstract][Full Text] [Related]
4. Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning.
Gaspar HB; Bjorkegren E; Parsley K; Gilmour KC; King D; Sinclair J; Zhang F; Giannakopoulos A; Adams S; Fairbanks LD; Gaspar J; Henderson L; Xu-Bayford JH; Davies EG; Veys PA; Kinnon C; Thrasher AJ
Mol Ther; 2006 Oct; 14(4):505-13. PubMed ID: 16905365
[TBL] [Abstract][Full Text] [Related]
5. Neonatal bone marrow transplantation of ADA-deficient SCID mice results in immunologic reconstitution despite low levels of engraftment and an absence of selective donor T lymphoid expansion.
Carbonaro DA; Jin X; Cotoi D; Mi T; Yu XJ; Skelton DC; Dorey F; Kellems RE; Blackburn MR; Kohn DB
Blood; 2008 Jun; 111(12):5745-54. PubMed ID: 18356486
[TBL] [Abstract][Full Text] [Related]
6. Update on gene therapy for adenosine deaminase-deficient severe combined immunodeficiency.
Ferrua F; Brigida I; Aiuti A
Curr Opin Allergy Clin Immunol; 2010 Dec; 10(6):551-6. PubMed ID: 20966749
[TBL] [Abstract][Full Text] [Related]
7. Hematopoietic stem cell gene therapy for adenosine deaminase deficient-SCID.
Aiuti A; Brigida I; Ferrua F; Cappelli B; Chiesa R; Marktel S; Roncarolo MG
Immunol Res; 2009; 44(1-3):150-9. PubMed ID: 19224139
[TBL] [Abstract][Full Text] [Related]
8. Clinical efficacy of gene-modified stem cells in adenosine deaminase-deficient immunodeficiency.
Shaw KL; Garabedian E; Mishra S; Barman P; Davila A; Carbonaro D; Shupien S; Silvin C; Geiger S; Nowicki B; Smogorzewska EM; Brown B; Wang X; de Oliveira S; Choi Y; Ikeda A; Terrazas D; Fu PY; Yu A; Fernandez BC; Cooper AR; Engel B; Podsakoff G; Balamurugan A; Anderson S; Muul L; Jagadeesh GJ; Kapoor N; Tse J; Moore TB; Purdy K; Rishi R; Mohan K; Skoda-Smith S; Buchbinder D; Abraham RS; Scharenberg A; Yang OO; Cornetta K; Gjertson D; Hershfield M; Sokolic R; Candotti F; Kohn DB
J Clin Invest; 2017 May; 127(5):1689-1699. PubMed ID: 28346229
[TBL] [Abstract][Full Text] [Related]
9. Gene therapy/bone marrow transplantation in ADA-deficient mice: roles of enzyme-replacement therapy and cytoreduction.
Carbonaro DA; Jin X; Wang X; Yu XJ; Rozengurt N; Kaufman ML; Wang X; Gjertson D; Zhou Y; Blackburn MR; Kohn DB
Blood; 2012 Nov; 120(18):3677-87. PubMed ID: 22833548
[TBL] [Abstract][Full Text] [Related]
10. Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction.
Gaspar HB; Cooray S; Gilmour KC; Parsley KL; Zhang F; Adams S; Bjorkegren E; Bayford J; Brown L; Davies EG; Veys P; Fairbanks L; Bordon V; Petropoulou T; Kinnon C; Thrasher AJ
Sci Transl Med; 2011 Aug; 3(97):97ra80. PubMed ID: 21865538
[TBL] [Abstract][Full Text] [Related]
11. Twenty-Five Years of Gene Therapy for ADA-SCID: From Bubble Babies to an Approved Drug.
Ferrua F; Aiuti A
Hum Gene Ther; 2017 Nov; 28(11):972-981. PubMed ID: 28847159
[TBL] [Abstract][Full Text] [Related]
12. [Transplantation of genetically modified cells in the treatment of children with SCID: great hopes and recent disappointments].
Smogorzewska EM; Weinberg KI; Kohn DB
Med Wieku Rozwoj; 2003; 7(1):27-34. PubMed ID: 13130167
[TBL] [Abstract][Full Text] [Related]
13. Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans.
Candotti F; Shaw KL; Muul L; Carbonaro D; Sokolic R; Choi C; Schurman SH; Garabedian E; Kesserwan C; Jagadeesh GJ; Fu PY; Gschweng E; Cooper A; Tisdale JF; Weinberg KI; Crooks GM; Kapoor N; Shah A; Abdel-Azim H; Yu XJ; Smogorzewska M; Wayne AS; Rosenblatt HM; Davis CM; Hanson C; Rishi RG; Wang X; Gjertson D; Yang OO; Balamurugan A; Bauer G; Ireland JA; Engel BC; Podsakoff GM; Hershfield MS; Blaese RM; Parkman R; Kohn DB
Blood; 2012 Nov; 120(18):3635-46. PubMed ID: 22968453
[TBL] [Abstract][Full Text] [Related]
14. Treatment of severe combined immunodeficiency disease (SCID) due to adenosine deaminase deficiency with CD34+ selected autologous peripheral blood cells transduced with a human ADA gene. Amendment to clinical research project, Project 90-C-195, January 10, 1992.
Blaese RM; Culver KW; Chang L; Anderson WF; Mullen C; Nienhuis A; Carter C; Dunbar C; Leitman S; Berger M
Hum Gene Ther; 1993 Aug; 4(4):521-7. PubMed ID: 7691188
[TBL] [Abstract][Full Text] [Related]
15. IL-3 or IL-7 increases ex vivo gene transfer efficiency in ADA-SCID BM CD34+ cells while maintaining in vivo lymphoid potential.
Ficara F; Superchi DB; Hernández RJ; Mocchetti C; Carballido-Perrig N; Andolfi G; Deola S; Colombo A; Bordignon C; Carballido JM; Roncarolo MG; Aiuti A
Mol Ther; 2004 Dec; 10(6):1096-108. PubMed ID: 15564141
[TBL] [Abstract][Full Text] [Related]
16. Gene therapy for severe combined immunodeficiencies.
Gaspar HB; Thrasher AJ
Expert Opin Biol Ther; 2005 Sep; 5(9):1175-82. PubMed ID: 16120048
[TBL] [Abstract][Full Text] [Related]
17. Transfer of the ADA gene into bone marrow cells and peripheral blood lymphocytes for the treatment of patients affected by ADA-deficient SCID.
Bordignon C; Mavilio F; Ferrari G; Servida P; Ugazio AG; Notarangelo LD; Gilboa E; Rossini S; O'Reilly RJ; Smith CA
Hum Gene Ther; 1993 Aug; 4(4):513-20. PubMed ID: 8399494
[TBL] [Abstract][Full Text] [Related]
18. Advances in gene therapy for ADA-deficient SCID.
Aiuti A
Curr Opin Mol Ther; 2002 Oct; 4(5):515-22. PubMed ID: 12435054
[TBL] [Abstract][Full Text] [Related]
19. Drug evaluation: ADA-transduced hematopoietic stem cell therapy for ADA-SCID.
Taupin P
IDrugs; 2006 Jun; 9(6):423-30. PubMed ID: 16752313
[TBL] [Abstract][Full Text] [Related]
20. Recombinant adeno-associated virus-mediated gene transfer for the potential therapy of adenosine deaminase-deficient severe combined immune deficiency.
Silver JN; Elder M; Conlon T; Cruz P; Wright AJ; Srivastava A; Flotte TR
Hum Gene Ther; 2011 Aug; 22(8):935-49. PubMed ID: 21142972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
